APA

Kereiakes D. J., Obenchain R. L., Barber B. L., Smith A., McDonald M., Broderick T. M., Runyon J. P., Shimshak T. M., Schneider J. F., Hattemer C. R., Roth E. M., Whang D. D., Cocks D. & Abbottsmith C. W. (20001102). Abciximab provides cost-effective survival advantage in high-volume interventional practice. : American heart journal.

Chicago

Kereiakes D J, Obenchain R L, Barber B L, Smith A, McDonald M, Broderick T M, Runyon J P, Shimshak T M, Schneider J F, Hattemer C R, Roth E M, Whang D D, Cocks D and Abbottsmith C W. 20001102. Abciximab provides cost-effective survival advantage in high-volume interventional practice. : American heart journal.

Harvard

Kereiakes D. J., Obenchain R. L., Barber B. L., Smith A., McDonald M., Broderick T. M., Runyon J. P., Shimshak T. M., Schneider J. F., Hattemer C. R., Roth E. M., Whang D. D., Cocks D. and Abbottsmith C. W. (20001102). Abciximab provides cost-effective survival advantage in high-volume interventional practice. : American heart journal.

MLA

Kereiakes D J, Obenchain R L, Barber B L, Smith A, McDonald M, Broderick T M, Runyon J P, Shimshak T M, Schneider J F, Hattemer C R, Roth E M, Whang D D, Cocks D and Abbottsmith C W. Abciximab provides cost-effective survival advantage in high-volume interventional practice. : American heart journal. 20001102.